The Globe and Mail
Published April 16, 2021
Bookmark
Moderna (STAR)
In the old days, people greeted each other with “Nice day” or “How are you?” Now, it’s “Hey, which vaccine did you get?” With AstraZeneca’s COVID-19 shot linked to very rare instances of blood clotting and the U.S. government temporarily suspending the use of Johnson & Johnson’s vaccine for similar reasons, shares of Moderna surged after the company said its jab showed “continued strong efficacy” six months after the second dose and has not been associated with clotting. Hey, Moderna, how about speeding up deliveries to your friends in Canada, eh?